Melanotan II: a possible cause of renal infarction: review of the literature and case report.
This paper presents a case report combined with a literature review examining a possible association between Melanotan II (MTII) — a non-selective melanocortin-receptor agonist commonly used illicitly for skin tanning, penile erection, and sexual stimulation — and renal infarction. The authors describe a patient who experienced renal infarction most likely attributed to MTII use. Renal infarction, an uncommon and potentially life-threatening condition caused by acute disruption of renal blood flow, is noted to be frequently misdiagnosed or diagnosed late. The paper reviews prior literature documenting MTII-associated rhabdomyolysis and renal failure, and proposes two potential mechanisms of renal injury: a thrombotic pharmacological effect and possible direct toxic effects on renal parenchyma. Limitations are significant: evidence rests on a single case and a narrative review of prior case-level reports, meaning causality cannot be formally established. No controlled data are available, and the condition's rarity makes systematic study difficult. The authors conclude that MTII's thrombotic and potentially nephrotoxic properties warrant clinical awareness, particularly given the compound's widespread unregulated use.
Why this grade: Evidence is limited to a single case report supplemented by a narrative literature review, with no control group or systematic methodology, preventing causal conclusions.
Renal infarction is an uncommon condition resulting from an acute disruption of renal blood flow and it is potentially life-threatening disease. The cause and outcome of renal infarction is not well established and is frequently misdiagnosed or diagnosed late. Melanotan II is a non-selective melanocortin-receptor agonist and its effect on humans is an increasing of skin pigmentation, producing of spontaneous penile erection and sexual stimulation. Melanotan II inducing rhabdomyolysis and renal failure have been described previously. We present a review of Melanotan II and the possible effects of this drug on the kidneys by including a case of a renal infarction most likely attributed to Melanotan II. In the mechanism of renal injury with Melanotan II, thrombotic pharmacological influence and possible direct toxic effect on renal parenchyma must be considered.
Educational summary of published research — not medical advice. Full text is shown only where licensing permits.